Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer

Journal of Clinical Oncology

Volumn 34, Issue 17, 2016, Pages 2003-2009

  Reeder Hayes, Katherine ^a   Hinton, Sharon Peacock ^a   Meng, Ke ^a   Carey, Lisa A ^a   Dusetzina, Stacie B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN;

AGED; ARTICLE; BREAST CANCER; CANCER STAGING; COMORBIDITY; DATA BASE; DRUG USE; FEMALE; HEALTH CARE NEED; HEALTH DISPARITY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MOLECULARLY TARGETED THERAPY; POISSON DISTRIBUTION; POVERTY; PRIORITY JOURNAL; RISK FACTOR; SOCIAL STATUS; VERY ELDERLY; AFRICAN AMERICAN; BIOSYNTHESIS; BREAST NEOPLASMS; CANCER REGISTRY; CAUCASIAN; COHORT ANALYSIS; ENZYMOLOGY; ETHNOLOGY; HEALTH CARE DISPARITY; METABOLISM; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HUMANS; MEDICARE; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; SEER PROGRAM; TRASTUZUMAB; TREATMENT OUTCOME; UNITED STATES;

EID: 84971664105     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.8716     Document Type: Article

References (35)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005
2. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
3. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
4. Perez EA, Romond EH, Suman VJ, et al: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32: 3744-3752, 2014
5. Reeder-Hayes KE, Carey LA: How low should we go? The search for balance in management of small human epidermal growth factor receptor 2- positive breast cancers. J Clin Oncol 32:2122-2124, 2014
6. Curigliano G, Viale G, Bagnardi V, et al: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699, 2009
7. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706, 2009
8. Fehrenbacher L, Capra AM, Quesenberry CP Jr, et al: Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2- positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: A cohort from an integrated health care delivery system. J Clin Oncol 32:2151-2158, 2014
9. Vaz-Luis I, Ottesen RA, Hughes ME, et al: Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: A multi-institutional study. J Clin Oncol 32:2142-2150, 2014
10. Freedman RA, Hughes ME, Ottesen RA, et al: Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119:839-846, 2013
11. Howlader N, Altekruse SF, Li CI, et al: US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106:dju055, 2014
12. Warren JL, Klabunde CN, Schrag D, et al: Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-IV-18, 2002 (suppl)
13. SEER: Derived HER2 Recode (2010+). http://seer.cancer.gov/seerstat/databases/ssf/her2-derived.html
14. Reeder-Hayes KE, Meyer AM, Dusetzina SB, et al: Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer. Breast Cancer Res Treat 145:743-751, 2014
15. Zaslavsky AM, Ayanian JZ, Zaborski LB: The validity of race and ethnicity in enrollment data for Medicare beneficiaries. Health Serv Res 47: 1300-1321, 2012
16. Arday SL, Arday DR, Monroe S, et al: HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev 21:107-116, 2000
17. McBean AM: Improving Medicare's data on race and ethnicity. Medicare Brief 15:1-7, 2006
18. a. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471-1474, 2010
19. Klabunde CN, Legler JM, Warren JL, et al: A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17:584-590, 2007
20. United States Census Bureau: Geographic terms and concepts - census tract, 2010. https://www.census.gov/geo/reference/gtc/gtc-ct.html
21. Zou G: A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 159:702-706, 2004
22. Aizer AA, Chen MH, McCarthy EP, et al: Marital status and survival in patients with cancer. J Clin Oncol 31:3869-3876, 2013
23. Yancik R, Wesley MN, Ries LA, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285: 885-892, 2001
24. Bigby J, Holmes MD: Disparities across the breast cancer continuum. Cancer Causes Control 16: 35-44, 2005
25. Schootman M, Jeffe DB, Lian M, et al: The role of poverty rate and racial distribution in the geographic clustering of breast cancer survival among older women: A geographic and multilevel analysis. Am J Epidemiol 169:554-561, 2009
26. Carpenter WR, Reeder-Hayes K, Bainbridge J, et al: The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation. Med Care 49:172-179, 2011
27. Wheeler SB, Reeder-Hayes KE, Carey LA: Disparities in breast cancer treatment and outcomes: Biological, social, and health system determinants and opportunities for research. Oncologist 18: 986-993, 2013
28. Hershman DL, Unger JM, Barlow WE, et al: Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol 27:2157-2162, 2009
29. Bickell NA, Wang JJ, Oluwole S, et al: Missed opportunities: Racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357-1362, 2006
30. Centers for Disease Control and Prevention (CDC): Vital signs: Racial disparities in breast cancer severity-United States, 2005-2009. MMWR Morb Mortal Wkly Rep 61:922-926, 2012
31. Rust G, Zhang S, Malhotra K, et al: Paths to health equity: Local area variation in progress toward eliminating breast cancer mortality disparities, 1990-2009. Cancer 121:2765-2774, 2015
32. Owusu C, Lash TL, Silliman RA: Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat 102:227-236, 2007
33. Tolaney SM, Barry WT, Dang CT, et al: Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372: 134-141, 2015
34. Black DM, Jiang J, Kuerer HM, et al: Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. JAMA Surg 149:788-796, 2014
35. Hassett MJ, Silver SM, Hughes ME, et al: Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 30: 2218-2226, 2012